All lobbying filings

FORBES-TATE

FORBES-TATE filed a Q3 report for PHRMA on October 19, 2026, reporting $80,000 in lobbying income.

Lobbying for PHRMA · A trade group representing the pharmaceutical research and biopharmaceutical companies

All filings by FORBES-TATE · Everything PHRMA has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$80,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Health Issues

Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.

Medicare/Medicaid

Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.

Pharmacy

Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.

Consumer Issues/Safety/Products

Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.

Trade (domestic/foreign)

Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.